ClinicalTrials.gg
CompletedNCT00699140ITPUpdated Feb 8, 2016Results posted

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura

A Phase 3 interventional study of IGIV3I Grifols in Immune (Idiopathic) Thrombocytopenic Purpura, sponsored by Instituto Grifols, S.A.. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 82 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.

Read the detailed description

To determine if IGIV3I Grifols 10% is a consistently effective treatment in patients diagnosed with immune thrombocytopenic purpura with respect to:

  1. Increase of platelet count ≥ 50x10\^9/L (primary objective).
  2. Time taken for the platelet count to reach ≥ 50x10\^9/L.
  3. The length of time the platelet count remains ≥ 50x10\^9/L.
  4. The maximum platelet level.
  5. Regression of bleeding episodes during the first 10 or 14 days.

To determine if IGIV3I Grifols 10% is safe with respect to:

Nature, severity and frequency of adverse reactions during and after infusions by percentage of subjects and percentage of infusions.

02

Conditions studied

  • Immune (Idiopathic) Thrombocytopenic Purpura
03

In context

Purpura, Thrombocytopenic

32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.

This study's enrollment of 18 is below the median of 54 across 22 interventional studies indexed under Purpura, Thrombocytopenic.

Browse Purpura, Thrombocytopenic studies →

Lead sponsor

Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be aged between 18 and 82 at the time of written consent.
  2. Have confirmed diagnosis of chronic ITP and fulfil all the following criteria:

    • irrelevant history except for the symptoms of bleeding,
    • pattern of bleedings associated with disorders,
    • physical examination irrelevant for the ITP, except for the signs of bleeding,
    • isolated thrombocytopenia in the blood count; apart from thrombocytopenia, the blood count is normal for the patient's age, or if abnormal, readily explained,
    • peripheral blood smear consistent with ITP: thrombocytopenia with platelets of normal size or slightly larger than normal, with absence of platelet clumps and giant platelets; normal red blood cell and white blood cell morphology,
    • confirmed diagnosis of immune thrombocytopenic purpura or, when any abnormal finding is present, additional diagnostic evaluation excludes other causes of thrombocytopenia.
    • Previous known diagnosis of ITP for at least 3 months.
  3. To show a platelet count platelet count ≤ 20x10\^9/L at the moment of the first infusion with the study product.
  4. Have read the patient information and consent sheet, agreed to participate in the trial, and signed the consent sheet.
  5. Be expected to receive treatment over 5 days and follow-up for 3 months.
  6. For women of childbearing age, use adequate method such as oral contraceptives, intrauterine device or tubal ligation during one-month period after the first infusion in the study.

Exclusion criteria

Exclusion Criteria:

  1. Have immune thrombocytopenia secondary to other pathologies or drug mediated thrombocytopenia.
  2. Have a known diagnosis of other diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
  3. Present important active bleeding due to other reasons apart from the ITP.
  4. Exhibit an identifiable alternative cause of their thrombocytopenia, such as splenomegaly, family thrombocytopenia, bacteraemia, sepsis or active infection requiring or not therapy.
  5. Are presenting renal dysfunction.
  6. Have non-controlled arterial hypertension.
  7. Have documented liver cirrhosis or any hepatic disorder with (ALT) levels 2.5 times or more than the normal upper limit or greater than 2 mg/dL.
  8. Are presenting a cardiac disease including a history of coronary artery disease, angina pectoris or congestive heart failure.
  9. Present known infection due to or virus (HCV).
  10. Have been previously treated with IVIG or anti-D immunoglobulin being unresponsive.
  11. Have a history of serious adverse reactions or non-serious but frequent adverse reactions to intravenous immune globulin (IVIG) preparations or other products derived from blood.
  12. Have known allergies to any IGIV3I Grifols components, such as D-sorbitol.
  13. Are simultaneously participating in other clinical studies or have received an drug in the 3 months prior to the start of the study.
  14. Have been involved in the present study and being treated with the formulation at 5% (IGIV3I Grifols 5%).
  15. Have conditions that might affect patient compliance.
  16. Are unable to provide a storage serum sample just before the first dose of IGIV3I Grifols.
  17. Are pregnant or nursing an infant child or unwilling to practice adequate in 1-month period after the first infusion in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    1 treatment group with IGIV3I Grifols

    Open label, non-randomized treatment group with IGIV3I Grifols Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses.

    Biological: IGIV3I Grifols

Interventions

  • BiologicalIGIV3I Grifols

    Immune Globulin Intravenous (Human)

    Also known as: IGIV

06

What researchers measure

Primary outcomes

  1. Responder Patients

    The primary efficacy endpoint was the proportion of patients who reached a platelet count ≥ 50x10\^9/L.

    Time frame: At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).

Secondary outcomes

  1. Maximum Platelet Level Reached During the Follow-up Period

    Platelet count was measured at various time points in the follow-up period after infusion.

    Time frame: During the follow-up period (time points: Days 6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])

  2. Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days)

    The time taken for the platelet count to reach ≥ 50x10\^9/L from first dose

    Time frame: At any time during the study period (time points: Days 1-6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])

  3. Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)

    Length of time platelet count remained ≥ 50x10\^9/L from first dose (Day 1)

    Time frame: At any time during the study period (up to 3 months [90 days])

  4. Regression of Hemorrhages.

    Percentage of subjects with regression of hemorrhages of Types 1 to 3: * Type 0: Patients without symptoms of bleeding at the first infusion continue without presenting spontaneous bleeding * Type 1: Patients with bleeding symptoms at the first infusion had a reduction of the size of large ecchymoses, and no spontaneous appearance of new ecchymoses * Type 2: Patients with bleeding symptoms at the first infusion had a decrease in the number of cutaneous petechiae, or the extent of the affected area of the body decreased * Type 3: Patients had active mucosal bleedings at the first infusion, these episodes stopped without re-bleeding, and there was no occurrence of new spontaneous mucosal hemorrhages (e.g., gingival bleeding, epistaxis)

    Time frame: First 10 to14 days since the first infusion day (Day 1)

  5. Frequency of Adverse Reactions During and After Infusions by Percentage of Patients

    All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of patients with at least one AE and adverse drug reactions are estimated.

    Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)

  6. Frequency of Adverse Reactions During and After Infusions by Percentage of Infusions

    All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of infusions associated with at least one AE and adverse drug reactions are estimated.

    Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)

  7. Changes in Vital Signs and Clinically Relevant Changes in Laboratory Parameters After the Infusions, Including Renal Function (Creatinine Levels)

    Laboratory parameters at each treatment day and visit are summarized by patient. Results were marked as normal/abnormal (whether the result is below, within or above the respective reference range) and relevant/irrelevant (as determined by the investigator). The number of abnormal values considered clinically relevant changes (based on the investigator's judgment) was listed.

    Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)

  8. Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA

    The results of HIV-1 and -2 antibodies, HCV antibody, HBsAg, HBV antibodies, HAV antibodies, HIV nucleic acid amplification test \[NAT\], and HCV NAT on Day 1, Day 14, and at Month 1, Month 2 and Month 3 were recorded for several of these markers (as appropriate). A comparison of negative viral markers on Day 1 and Month 3 was performed

    Time frame: At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)

07

Results

Posted Feb 8, 2016
Limitations and caveats
The patient number was based on European Medicines Agency guidance to evaluate IVIG products in ITP patients (EMEA/CPMP/BPWG/388/95 rev.1, June 2000, in force when the study was designed): at least 15 subjects were sufficient for the analysis.

Participant flow

Participant flow — Overall Study
Milestone1 Treatment Group With IGIV3I
Started18
Completed18
Not completed0

Outcome measures

PrimaryResponder Patients

The primary efficacy endpoint was the proportion of patients who reached a platelet count ≥ 50x10\^9/L.

Time frame:
At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).
Reported as:
Number · percentage of subjects
Responder Patients
percentage of subjects1 Treatment Group With IGIV3I
Responder Patients72.2 (50.2 to 88.4)
SecondaryMaximum Platelet Level Reached During the Follow-up Period

Platelet count was measured at various time points in the follow-up period after infusion.

Time frame:
During the follow-up period (time points: Days 6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])
Reported as:
Median · platelets x 10^-9/L
Maximum Platelet Level Reached During the Follow-up Period
platelets x 10^-9/L1 Treatment Group With IGIV3I
Maximum Platelet Level Reached During the Follow-up Period146.0 (71.0 to 763.0)
SecondaryTime to Reach Platelet Count ≥ 50x10^9/L (≤ Days)

The time taken for the platelet count to reach ≥ 50x10\^9/L from first dose

Time frame:
At any time during the study period (time points: Days 1-6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])
Reported as:
Median · days
Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days)
days1 Treatment Group With IGIV3I
Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days)2 (0 to 5)
SecondaryLength of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)

Length of time platelet count remained ≥ 50x10\^9/L from first dose (Day 1)

Time frame:
At any time during the study period (up to 3 months [90 days])
Reported as:
Median · days
Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)
days1 Treatment Group With IGIV3I
Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)9 (3 to 61)
SecondaryRegression of Hemorrhages.

Percentage of subjects with regression of hemorrhages of Types 1 to 3: * Type 0: Patients without symptoms of bleeding at the first infusion continue without presenting spontaneous bleeding * Type 1: Patients with bleeding symptoms at the first infusion had a reduction of the size of large ecchymoses, and no spontaneous appearance of new ecchymoses * Type 2: Patients with bleeding symptoms at the first infusion had a decrease in the number of cutaneous petechiae, or the extent of the affected area of the body decreased * Type 3: Patients had active mucosal bleedings at the first infusion, these episodes stopped without re-bleeding, and there was no occurrence of new spontaneous mucosal hemorrhages (e.g., gingival bleeding, epistaxis)

Time frame:
First 10 to14 days since the first infusion day (Day 1)
Reported as:
Number · percentage of subjects
Regression of Hemorrhages.
percentage of subjects1 Treatment Group With IGIV3I
Regression of Hemorrhages.83.3 (62.3 to 95.3)
SecondaryFrequency of Adverse Reactions During and After Infusions by Percentage of Patients

All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of patients with at least one AE and adverse drug reactions are estimated.

Time frame:
At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Reported as:
Number · percentage of patients
Frequency of Adverse Reactions During and After Infusions by Percentage of Patients
percentage of patients1 Treatment Group With IGIV3I
Frequency of patients with AEs88.9
Frequency of patients with adverse drug reactions38.9
SecondaryFrequency of Adverse Reactions During and After Infusions by Percentage of Infusions

All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of infusions associated with at least one AE and adverse drug reactions are estimated.

Time frame:
At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Reported as:
Number · percentage of infusions
Frequency of Adverse Reactions During and After Infusions by Percentage of Infusions
percentage of infusions1 Treatment Group With IGIV3I Grifols
Frequency of infusions with adverse events26.3
Frequency of infusions with adverse drug reactions24.6
SecondaryChanges in Vital Signs and Clinically Relevant Changes in Laboratory Parameters After the Infusions, Including Renal Function (Creatinine Levels)

Laboratory parameters at each treatment day and visit are summarized by patient. Results were marked as normal/abnormal (whether the result is below, within or above the respective reference range) and relevant/irrelevant (as determined by the investigator). The number of abnormal values considered clinically relevant changes (based on the investigator's judgment) was listed.

Time frame:
At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Reported as:
Number · participants
Changes in Vital Signs and Clinically Relevant Changes in Laboratory Parameters After the Infusions, Including Renal Function (Creatinine Levels)
participants1 Treatment Group With IGIV3I Grifols
Clinically relevant changes in vital signs0
Clinically relevant changes in lab parameters7
SecondaryViral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA

The results of HIV-1 and -2 antibodies, HCV antibody, HBsAg, HBV antibodies, HAV antibodies, HIV nucleic acid amplification test \[NAT\], and HCV NAT on Day 1, Day 14, and at Month 1, Month 2 and Month 3 were recorded for several of these markers (as appropriate). A comparison of negative viral markers on Day 1 and Month 3 was performed

Time frame:
At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Reported as:
Number · seroconversions
Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA
seroconversions1 Treatment Group With IGIV3I
Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA0

Adverse events

Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 Treatment Group With IGIV3I Grifols—2/18 (11.1%)12/18 (66.7%)
Most frequent serious events
Most frequent serious events
Event1 Treatment Group With IGIV3I Grifols
ThrombosisVascular disorders1/18
Haemoglobin decreasedInvestigations1/18
LeukopeniaBlood and lymphatic system disorders1/18
Most frequent other events
Showing 10 of 29
Most frequent other events
Event1 Treatment Group With IGIV3I Grifols
PetechiaeSkin and subcutaneous tissue disorders12/18
EcchymosisSkin and subcutaneous tissue disorders8/18
HeadacheNervous system disorders7/18
PyrexiaGeneral disorders4/18
RashSkin and subcutaneous tissue disorders2/18
ChillsGeneral disorders2/18
Gingival bleedingGastrointestinal disorders2/18
HypertensionVascular disorders2/18
Palmar erythemaSkin and subcutaneous tissue disorders1/18
FatigueGeneral disorders1/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1 Treatment Group With IGIV3I
<=18 years0
Between 18 and 65 years16
>=65 years2
Age, Continuous
Age, Continuous(years)1 Treatment Group With IGIV3I
Median43 (20 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)1 Treatment Group With IGIV3I
Female12
Male6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 Treatment Group With IGIV3I
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)1 Treatment Group With IGIV3I
Russian Federation12
United Kingdom2
Spain4
Subjects with medical history of splenectomy
Subjects with medical history of splenectomy(participants)1 Treatment Group With IGIV3I
Yes9
No9
Subjects with haemorrhagic history
Subjects with haemorrhagic history(participants)1 Treatment Group With IGIV3I
Yes13
No5
Platelet count
Platelet count(platelets x 10^-9/L)1 Treatment Group With IGIV3I
Median8.5 (3.0 to 36.0)
08

Study locations

7 sites
  • Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology Roszdrava
    Moscow, Russian Federation
  • Haematology Research Centre of Russian Academy of Medical Science
    Moscow, Russian Federation
  • Hospital General Vall d´Hebron
    Barcelona, Spain
  • . Hospital de León
    Leon, Spain
  • Hospital General Universitario La Paz
    Madrid, Spain
  • Hospital Universitario La Fe
    Valencia, Spain
  • Hillingdon Hospital
    Middlesex, UB8 3NN, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2008
First posted
Jun 17, 2008
Start
Feb 2008
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Feb 8, 2016
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00699140
Responsible party
Sponsor
First posted
Jun 17, 2008
Start date
Feb 2008
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Feb 8, 2016
Last update
Feb 8, 2016

Study contacts

María Teresa Álvarez, MD
principal investigator · Hospital General Universitario La Paz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion